142 related articles for article (PubMed ID: 30446313)
21. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.
Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW
Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045
[TBL] [Abstract][Full Text] [Related]
22. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
23. Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors.
Pacheco Dda F; Romero TR; Duarte ID
Brain Res; 2014 May; 1562():69-75. PubMed ID: 24675031
[TBL] [Abstract][Full Text] [Related]
24. The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.
Tsuruda PR; Vickery RG; Long DD; Armstrong SR; Beattie DT
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jun; 386(6):479-91. PubMed ID: 23549670
[TBL] [Abstract][Full Text] [Related]
25. Discovery of N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenol and -phenyl carboxamide series of μ-opioid receptor antagonists.
Jiang L; Beattie DT; Jacobsen JR; Kintz S; Obedencio GP; Saito D; Stergiades I; Vickery RG; Long DD
Bioorg Med Chem Lett; 2017 Jul; 27(13):2926-2930. PubMed ID: 28499731
[TBL] [Abstract][Full Text] [Related]
26. Expression and localization of delta-, kappa-, and mu-opioid receptors in human spermatozoa and implications for sperm motility.
Agirregoitia E; Valdivia A; Carracedo A; Casis L; Gil J; Subiran N; Ochoa C; Irazusta J
J Clin Endocrinol Metab; 2006 Dec; 91(12):4969-75. PubMed ID: 16984994
[TBL] [Abstract][Full Text] [Related]
27. The mesolimbic system participates in the naltrexone-induced reversal of sexual exhaustion: opposite effects of intra-VTA naltrexone administration on copulation of sexually experienced and sexually exhausted male rats.
Garduño-Gutiérrez R; León-Olea M; Rodríguez-Manzo G
Behav Brain Res; 2013 Nov; 256():64-71. PubMed ID: 23933468
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of 7β-hydroxy-8-ketone opioid derivatives with antagonist activity at mu- and delta-opioid receptors.
Ahonen TJ; Rinne M; Grutschreiber P; Mätlik K; Airavaara M; Schaarschmidt D; Lang H; Reiss D; Xhaard H; Gaveriaux-Ruff C; Yli-Kauhaluoma J; Moreira VM
Eur J Med Chem; 2018 May; 151():495-507. PubMed ID: 29649744
[TBL] [Abstract][Full Text] [Related]
29. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats.
Shannon HE; Lutz EA
Neuropharmacology; 2002 Feb; 42(2):253-61. PubMed ID: 11804622
[TBL] [Abstract][Full Text] [Related]
31. Disruption of morphine-conditioned place preference by a delta2-opioid receptor antagonist: study of mu-opioid and delta-opioid receptor expression at the synapse.
Billa SK; Xia Y; Morón JA
Eur J Neurosci; 2010 Aug; 32(4):625-31. PubMed ID: 20626460
[TBL] [Abstract][Full Text] [Related]
32. Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.
Beaudry H; Gendron L; Morón JA
Eur J Neurosci; 2015 Apr; 41(7):901--7. PubMed ID: 25639561
[TBL] [Abstract][Full Text] [Related]
33. Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
Zheng Y; Obeng S; Wang H; Stevens DL; Komla E; Selley DE; Dewey WL; Akbarali HI; Zhang Y
ACS Chem Neurosci; 2018 Dec; 9(12):3028-3037. PubMed ID: 30001114
[TBL] [Abstract][Full Text] [Related]
34. Clinically employed opioid analgesics produce antinociception via μ-δ opioid receptor heteromers in Rhesus monkeys.
Yekkirala AS; Banks ML; Lunzer MM; Negus SS; Rice KC; Portoghese PS
ACS Chem Neurosci; 2012 Sep; 3(9):720-7. PubMed ID: 23019498
[TBL] [Abstract][Full Text] [Related]
35. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
36. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
[TBL] [Abstract][Full Text] [Related]
37. Effects of opioid antagonists on unconditioned and conditioned hyperactivity to morphine.
Rauhut AS; Gehrke BJ; Phillips SB; Bardo MT
Pharmacol Biochem Behav; 2002 Oct; 73(3):611-22. PubMed ID: 12151036
[TBL] [Abstract][Full Text] [Related]
38. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
[TBL] [Abstract][Full Text] [Related]
39. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
Ananthan S
AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
[TBL] [Abstract][Full Text] [Related]
40. Prolonged morphine treatment alters δ opioid receptor post-internalization trafficking.
Ong EW; Xue L; Olmstead MC; Cahill CM
Br J Pharmacol; 2015 Jan; 172(2):615-29. PubMed ID: 24819092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
